Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the advance notice published in English and vernacular language (Gujarati) newspaper on 16th September, 2022 in Economic Times and Indian Express, English Edition and Financial Express Gujarati Edition, in compliance with Ministry of Corporate Affair's General Circular No. 20/2020 dated 5th May, 2020 inter alia informing the members that the 12th Annual General Meeting of the Company will be held on Friday, the 11th November, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). We request you to kindly take the same on record.
16-09-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

 With reference to our letter under reference, we had informed the exchange that the Hon'ble National Company Law Tribunal, Ahmedabad Bench vide its Order dated 29th August, 2022 has sanctioned the Scheme of Arrangement in the nature of Amalgamation between Aleor Dermaceuticals Limited and Alembic Pharmaceuticals Limited and their respective shareholders ('Scheme') pursuant to the provisions of Section 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules made thereunder. The updated Memorandum of Association ('MOA') & Articles of Association ('AOA') after giving effect to the Scheme is placed on the website of the Company at the following web-link: https://alembicpharmaceuticals.com/moa-aoa/
14-09-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisements related to i) notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) and/or their legal heir(s) in Business Standard (English edition) on 9th September, 2022 and ii) notice for claiming shares from Company's Unclaimed Suspense Account published by the Company in Business Standard (English edition) on 9th September, 2022. We request you to kindly take the same on record.
09-09-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company has met analysts/investors through KIE Healthcare Forum hosted by Kotak Securities Limited on 8th September, 2022. We request you to kindly take the same on record.
08-09-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 8th September, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s). We request you to kindly take the same on record.
08-09-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - USFDA Inspection At Alembic Pharmaceuticals Injectable Facility (F-3) At Karkhadi

 We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' Injectable Facility (F-3) located at Karkhadi from 18th August, 2022 to 30th August, 2022. The USFDA issued a Form 483 with 2 observations. None of the observations are related to data integrity and management believes that they are addressable. The Company is preparing the response to the observations, which will be submitted to the USFDA within stipulated period. The Company is committed to maintain the highest quality standards and compliance at all times. We request you to kindly take the same on record.
01-09-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

 We would like to inform that Hon''ble National Company Law Tribunal, Ahmedabad Bench ("NCLT"), vide its Order dated 29th August, 2022, has sanctioned the Scheme of Arrangement in the nature of Amalgamation between Aleor Dermaceuticals Limited and Alembic Pharmaceuticals Limited and their respective shareholders ("Scheme") pursuant to the provisions of Section 230 to 232 and other applicable provisions of the Companies Act, 2013 and rules made thereunder. A copy of the said Order is available on the website of the Company. The Scheme will become effective upon filing of the said Order with the Registrar of Companies, Gujarat. We request you to kindly take the same on record.
01-09-2022

Alembic Pharma gets USFDA nod for blood pressure drug

 The company has received final approval from the US Food and Drug Administration (USFDA) to market the product in the US in strengths of 25 mg and 50 mg, the drug maker said in a statement.
29-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Successful USFDA RRA At Alembic Pharmaceuticals Bioequivalence Facility (Bio-Analytical Division) At Vadodara

 This is to inform the exchange that the Company has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations. The RRA was conducted from 22nd August, 2022 to 26th August, 2022. We request you to kindly take the same on record.
29-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
29-08-2022
Next Page
Close

Let's Open Free Demat Account